Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness by Ylivinkka, Irene et al.
RESEARCH Open Access
Motility of glioblastoma cells is driven by
netrin-1 induced gain of stemness
Irene Ylivinkka1,2, Harri Sihto1, Olli Tynninen3, Yizhou Hu1, Aki Laakso4, Riku Kivisaari4, Pirjo Laakkonen1,
Jorma Keski-Oja1,2 and Marko Hyytiäinen1,5*
Abstract
Background: Glioblastoma is an untreatable brain cancer. The tumors contain a population of stem-like cells which
are highly invasive and resistant to therapies. These cells are the main reason for the lethality of glioblastoma.
Extracellular guidance molecule netrin-1 promotes the invasiveness and survival of various cancer cell types. We
have previously found that netrin-1 activates Notch signaling, and Notch signaling associates with cell stemness.
Therefore, we have here investigated the effects of netrin-1 on glioblastoma pathogenesis and glioblastoma cell
stemness.
Methods: Glioma tissue microarrays were stained with immunohistochemistry and the results were used to
evaluate the association between netrin-1 and survival of glioma patients. The localization of netrin-1 was analyzed
utilizing fresh frozen glioblastoma tissues. The glioma cell invasion was investigated using ex vivo glioma tissue
cultures and newly established primary cell cultures in 3D in vitro invasion assays. Intracranial mouse xenograft
models were utilized to investigate the effects of netrin-1 on glioblastoma growth and invasion in vivo.
Results: Netrin-1 expression associated with poor patient prognosis in grade II-III gliomas. In addition, its expression
correlated with the stem-like cell marker nestin. Netrin-1 overexpression in cultured cells led to increased formation
of stem-like cell spheroids. In glioblastoma tumor biopsies netrin-1 localized to hypoxic tumor areas known to be
rich in the stem-like cells. In xenograft mouse models netrin-1 expression altered the phenotype of non-invasive
glioblastoma cells into diffusively invading and increased the expression of glioma stem-like cell markers.
Furthermore, a distinct invasion pattern where netrin-1 positive cells were following the invasive stem-like cells was
detected both in mouse models and ex vivo human glioblastoma tissue cultures. Inhibition of netrin-1 signaling
targeted especially the stem-like cells and inhibited their infiltrative growth.
Conclusions: Our findings describe netrin-1 as an important regulator of glioblastoma cell stemness and motility.
Netrin-1 activates Notch signaling in glioblastoma cells resulting in subsequent gain of stemness and enhanced
invasiveness of these cells. Moreover, inhibition of netrin-1 signaling may offer a way to target stem-like cells.
Keywords: Netrin, Glioma, Glioblastoma, Glioblastoma stem-like cell, Cancer stem cell, Notch signalling, Cell
invasion
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Background
Glioblastoma (GBM) is the most common primary hu-
man brain tumor. Despite the research efforts during re-
cent years this cancer has remained incurable. The
median survival time of patients is 15 months after diag-
nosis. GBMs are extremely heterogenous tumors with
high invasive capability. The tumors are rich in cells that
possess characteristics of stem cells [15, 35, 36]. These
cells, named GBM stem-like cells, show self-renewing
capability, can differentiate into different brain tumor
cell types and express various neural stem cell markers.
GBM stem-like cells are suggested to be the main reason
for the lethality of GBMs because of their invasiveness
and resistance to radiotherapy [3].
Netrin-1 (NTN1) is a secreted component of the
extracellular matrix [31]. Its main function is to guide
the developing axons into their correct targets during
embryogenesis [30]. Within recent years NTN1 has
shown out to be essential for the tumorigenesis of differ-
ent cancers including neuroblastoma, non-small cell
lung cancer, pancreatic adenocarcinoma, metastatic
breast cancer and colorectal cancer [9–11, 13, 20, 27].
We and others have observed that NTN1 can enhance
the invasive phenotype of GBM cells [33, 41]. Further-
more, we have shown that the increase in in vitro inva-
siveness is mediated by NTN1 induced activation of
Notch signaling [41].
Based on the previous findings we explored the role of
NTN1 using human GBM samples and in vivo models.
Because Notch signaling is also essential for the main-
tenance and motility of GBM stem-like cells [12, 17] we
analyzed how NTN1 affects these cells. We report here
that NTN1 is associated with poor patient prognosis in
low grade gliomas. In addition, its expression correlates
with the GBM stem-like cell marker nestin. In xenograft
models NTN1 expression converted the phenotype of
non-invasive GBM cells into diffusively invading and in-
creased the expression of GBM stem-like cell markers.
Furthermore, NTN1 and Notch signaling inhibition with
recombinant NTN1 derived peptide restricted the GBM
stem-like cell infiltrative growth in vivo. These findings
provide new information on the regulation of GBM
stem-like cells and their motility.
Methods
Reagents and antibodies
NTN1 recognizing antibody (CH23002) was obtained
from Neuromics. Monoclonal antibody against CD133
(W6B3C1, MACS Miltenyi), polyclonal antibody against
nestin (3579, Millipore) and polyclonal antibody against
Sox2 (Cell Signaling) were used to recognize the stem-
ness markers of GBM cells. Anti hemaglutinin anti-
bodies from Covance (HA-11) and from Sigma-Aldrich
(clone 3 F10) were used to recognize tagged NTN1. The
tumor vasculature was stained with mouse CD31 recog-
nizing antibody from R&D Systems. Notch2 extracellular
domain (25–255) and intracellular domain (D67C8) rec-
ognizing antibodies were obtained from Santa Cruz Bio-
technology and Millipore respectively. Antibody
recognizing cleaved Notch2 (D1733) was obtained from
Immunoway. Intracellular domain of Jagged1 (C-20) rec-
ognizing polyclonal antibody was obtained from Santa
Cruz Biotechnology. Human specific lamin A/C anti-
body (Novus Bio) was used to distinguish human tumor
cell in mice xenografts. The fluorochrome conjugated
Alexa secondary antibodies used in immunofluorescence
microscopy were purchased from Invitrogen. The nuclei
were visualized with Hoechst 44432 (Invitrogen). Re-
combinant human EGF, basic FGF and NTN1 proteins
were obtained from R&D Systems. Growth factor re-
duced Matrigel was obtained from Corning.
Cell-lines and culturing
U87MG (ATCC), U251MG (Health Sciences Research
Resources Bank, Japan) and U373MG cells (obtained
from Dr. Bengt Westermark, Uppsala) cells were grown
in Dulbecco’s modified essential culture medium
(DMEM) supplied with 10% heat inactivated fetal calf
serum (FCS) (Gibco, USA), 100 IU/ml penicillin, 50 mg/
ml streptomycin and 1% L-glutamine. 293FT cells (Invi-
trogen, USA) were grown in DMEM supplied with
4.5 μg/ml glucose, 10% heat inactivated FCS, 100 IU/ml
penicillin, 50 mg/ml streptomycin and 1% L-glutamine.
Primary GBM cells, GBM9 and GBM10, were grown in
DMEM/F12 cell culture medium (Gibco) supplemented
with 100 IU/ml penicillin, 50 mg/ml streptomycin,
20 ng/ml basic fibroblast growth factor (bFGF, R&D Sys-
tems), 20 ng/ml epidermal growth factor (EGF, R&D
Systems), B27 supplement without vitamin A (Gibco).
Human tumor tissue biopsies
The use of human tumor tissue and clinical data was ap-
proved by the Operative Division of the Ethical Commit-
tee of Helsinki University Hospital and The National
Supervisory Authority for Welfare and Health. Tumor
tissue samples were collected from the archives of De-
partment of Pathology, Helsinki University Central Hos-
pital, Finland and tissue microarrays were constructed
from representative tumor areas. Two paraffin embed-
ded tissue microarrays were studied: an array containing
112 low grade glioma samples previously described in
[38] and an array consisting of 40 primary GBMs [34].
The tumors were diagnosed and graded according to the
WHO 2007 classification [22]. 1p/19q codeletion status
was available for 35% of the oligodendroglial tumors. For
the rest of the oligodendrocytic tumors the correct clas-
sification was ensured with p53 immunohistochemistry.
Only samples whose histological type, grade, gender, age
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at the time of diagnosis, follow-up time until death and
successful NTN1 staining were available, were included
in analyses.
In addition, we collected fresh GBM tumor biop-
sies directly from the surgery. The study protocol for
obtaining patient samples was approved by the
Operative Division of the Ethical Committee of
Helsinki University Hospital. All patients gave their
written informed consent. The inclusion criteria were
age over 18 years, recent magnetic resonance im-
aging demonstrating a brain tumor with typical
GBM appearance, and such tumor location that suf-
ficient, representative tumor biopsy (approximately
1 cm3) could be safely obtained during tumor resec-
tion. Additional tumor biopsies were collected for
routine clinical immunohistopathological analysis.
The tissue was washed with DMEM/F12, embedded
into OCT compound (Sakura Biotech) in a cryomold
and fresh frozen using liquid nitrogen. After freezing
the tissueblock was stored a −80 °C. For immuno-
fluorescence staining 7 μm thick sections were cut
with Cryotome (Sakura Biotech) and transferred onto
microscope slides for staining. The slides were either
stained directly or stored in −20 °C.
Immunohistochemical staining of paraffin embedded
tissue
To evaluate the expression of NTN1 using immunohis-
tochemistry, 5 μm thick tumor sections were cut on
SuperFrost+ slides (Menzel-Gläser). First the sections
were deparaffinized in xylene and rehydrated in a de-
creasing ethanol gradient series. Endogenous peroxidase
activity was quenched by incubating the sections in 3%
hydrogen peroxide for 30 min. After that, the epitope
was retrieved using heat induced epitope retrieval in so-
dium citrate buffer (10 mmol/L, pH 6.0). Sections were
autoclaved 120 °C for 2 min. Next, the NTN1 antibody
dilution was administered to the sections and incubated
overnight in +4°. Primary NTN1 antibody was detected
using rabbit anti chicken secondary antibody followed
with ImmPress (Vector laboratories) staining kit used
according to manufacturer’s instruction. The bound
NTN1 antibody was finally detected with a DAB Perox-
idase Substrate Kit (Vector Laboratories) 15 min at
room temperature. The slides were counterstained using
hematoxylin. Kidney tissue was used as positive control.
The NTN1 staining was classified as either positive or
negative. Immunohistochemistry protocol to stain nestin
is described elsewhere [28].
Lentiviral gene transduction
Cells stably expressing firefly luciferase and NTN1, or
green fluorescent protein and NTN1 were produced
with lentiviral transduction as previously described in
[41]. Shortly, lentiviruses were produced in 293FT cells
by Turbofect (Thermo Fisher Scientific) transfection ac-
cording to manufacturer’s instructions. Viruses were col-
lected and virus titer determined 48 h after transfection.
Target cells were infected with then infected with tit-
tered lentiviruses. For intracranial xenograft experiments
U87MG and U373MG cells were transduced with a
pLVX-hygro plasmid carrying LUC2 firefly luciferase
gene (Promega). Stable LUC2 expressing cell pools were
selected with 200 μg/ml hygromycine (Sigma-Aldrich)
for 48 h. These cells were further transduced with either
pLVX-puro vector, full-length NTN1 fused with Flag or
hemagglutinin (HA) tags (NTN1FH) or with NTN1 cen-
tral fragment (amino acids 282–486 of full-length
NTN1) fused with Flag and HA tags (NTN1(II)FH) [41].
The transduced cells were selected by administering
5 μg/ml puromycine (Calbiochem) in their culture
medium. The efficiency of the overexpression of LUC2
and NTN1 was evaluated by bioluminescence quantita-
tion and western blotting.
For 3D cell invasion assays U251MG cells stably ex-
pressing empty pLVX-Puro vector, NTN1FH or
NTN1(II)FH were further lentivirally transduced with
pLenti CMV GFP Puro plasmid. The pLenti CMV GFP
Puro plasmid was a gift from Eric Campeau (Addgene
#17448) [14]. Pool of GFP positive cells were then sorted
with fluorescence activated cell sorting using Sony
SH800Z Cell Sorter.
Orthotopic glioblastoma xenografts
All experimental procedures involving mice were autho-
rized by the National Animal Experiment Board.
U87MG and U373MG cells expressing either firefly lu-
ciferase and NTN1FH or NTN1(II)FH were implanted
into the brain of BALB/C NU/NU athymic mice. Five
mice per cell-line were used. Intracranial implantation of
the cells was performed as previously published [18, 24].
Shortly, cells were trypsinized, counted and suspended
into PBS. 150 000 cells in 5 μl were loaded into the
Hamilton needle. The mice were anaesthetized using
combination of ketamine and xylazine. Skin on mouse
scalp was opened with sagittal incision and a hole was
drilled into the mouse scull. The hole was positioned
2 mm right and 1 mm anterior to the bregma suture.
Using stereotactic device and the Hamilton needle was
inserted 3 mm deep into the mouse brain. After 1 min
the needle was lifted 0,5 mm. The cells were injected
into the brain during 2 min and allowed to stabilize for
1 min. After injection the Hamilton needle was slowly
removed, the injection hole on the skull was covered
with bone wax and the wound closed with a stitch. The
recovery of the mice was enhanced by administering
Temgesic (RB Pharmaceuticals) 0,3 μg/mouse on the op-
eration day and on two following days.
Ylivinkka et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:9 Page 3 of 18
The tumor growth was followed with bioluminescence
imaging. 3 mg of D-Luciferin (Regis Technologies) in
PBS was administered subcutaneously to each mouse
and allowed to circulate for 15 min. The mice were
anaesthetized with isoflurane and the emitted photons
were measured using Perkin-Elmer IVIS 100 imaging
system. In addition, the weight of the mice was moni-
tored regularly to evaluate their physical condition. The
mice were sacrificed 21 days after U87MG implantations
and 52 days after U373MG implantation.
After sacrificing the mice their brain was immediately
collected and fixed with 4% paraformaldehyde in phos-
phate buffered saline (PBS) for 30 min. The tissue was
then washed with PBS and incubated with 30% sucrose
for 24 h. After that the tissue was embedded into OCT
compound (Sakura Bioteh) in a cryomold (Sakura Bio-
tech) and frozen using liquid nitrogen. The frozen tissue
blocks were stored in −80 °C. For immunofluorescence
staining, 7 μm thick sections were prepared and trans-
ferred onto SuperFrost+ slides (Menzel-Gläser). Slides
were either processed immediately or stored in −20 °C.
Tissue immunofluorescence staining
Frozen tissue of both mice and human were used for im-
munofluorescence stainings. Frozen, paraffin fixed
mouse tissue sections were melted in room temperature
for 5 min, fixed with cold acetone 10 min and washed
with PBS. The unfixed, fresh-frozen human tumor biop-
sies were melted and washed with PBS. The following
procedures were same for both tissue types. The unspe-
cific binding of primary antibody was prevented by incu-
bating the sample for 30 min with 0,5% casein in tris
buffered saline (TBS) (blocking buffer). Tissue was incu-
bated with primary antibody diluted to blocking buffer
at +4 °C overnight. Next, slides were washed with 0,05%
Tween in TBS and re-incubated with blocking buffer.
Fluorescent labelled secondary antibody and Hoechst for
recognizing nuclei were diluted to blocking buffer, ad-
ministered to the tissue sections and incubated at room
temperature for 1 h. Slides were washed with 0,05%
Tween in TBS and distilled water. After that slides were
mounted with Mowiol mounting medium (Sigma) and
covered with cover glass (Menzel). Tissues were ana-
lyzed under either Zeiss Axioplan fluorescence micro-
scope, Zeiss LSM 880 Confocal microscope or Zeiss
Axio Imager.Z1 upright epifluorescence microscope.
Ex vivo GBM tissue culture
Fresh GBM tissue biopsies were rinsed with DMEM/F12
and cut into 2 mm X 2 mm pieces. Each tissue piece
was then embedded into 50 μl of growth factor reduced,
phenol free Matrigel (Corning) and transferred on to a
center of a well of 24-well cell culture plate (Thermo-
Scientific). The Matrigel was allowed to polymerize for
30 min. DMEM/F12 supplemented with 100 IU/ml peni-
cillin, 50 mg/ml streptomycin, EGF 20 ng/ml (R&D sys-
tems), bFGF 20 ng/ml (R&D systems) and vitamin A
depleted B27 supplement (Gibco) was administered to
the well. The growth of the tumor was assessed under
Zeiss Axiovert 200 inverted transmitted light micro-
scope. The tumor tissue was allowed to grow until half
of the area of the Matrigel drops were covered by the
sprouting tumor cells, typically 7 days. The drops were
then transferred into OCT compound (Sakura Biotech)
filled cryomolds (Sakura Biotech), frozen and stored
similarly as GBM tissue biopsies.
In vitro cell proliferation assay
Proliferating cells were labelled using Click-IT EdU Im-
aging Kit (Life Technologies) following the standard
protocol of the manufacturer. In short, U87MG or
U373MG cells were pulsed with 10 μM of EdU for
60 min prior to fixation. Cells were stained using Click-
IT EdU Imaging Kit with AlexaFluor-594 conjugate
(Thermo Scientic). The nuclei were visualized with 5 μg/
ml of Hoechst 44432 (Invitrogen). The proliferation rate
was analyzed using ANIMA software [29]. In short, cells
were segmented for nuclear Hoechst signal. Resulting
nuclear masks were used to measure the intensities of
EdU. The EdU positive cells were selected by k-means
clustering algorithm and the proliferation ratio was de-
termined by dividing the total cell number with EdU la-
belled cell number.
Neurosphere formation assay
Cells were harvested by trypsinization and washed with
serum-free DMEM/F12 medium (Lonza). Cells were pel-
leted by centrifugating 500 g 5 min and resuspended
into DMEM/F12 medium supplied with 50u/ml Penisil-
lin, 50 μg/ml Streptomycine, 20 ng/ml bFGF (R&D Sys-
tems), 20 ng/ml EGF (R&D Systems) and B27 (Gibco).
100 cells were seeded per well on a 96-well plate. Cells
were incubated for 3 weeks and the number of the
formed neurospheres was quantitated. The stemness of
neurspheres was ensured by examining their mRNA ex-
pression of GBM stem-like cell markers nestin, Sox2
and integrin alpha 6 with quantitative real time PCR.
RNA from the cells was collected and real-time PCR
was performed as described earlier [41]. The primers for
the analysis were obtained from Applied Biosystems.
The expression levels were normalized to the expression
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and compared to wildtype U251MG cells.
Neurosphere invasion assays
The Boyden chamber invasion assays were performed as
previously described in [41]. Shortly, U251MG neuro-
spheres were collected, dissociated and plated on top of
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Matrigel coated Boyden chamber. Either DMEM/F12 as
such or supplemented with 50 ng/ml of recombinant
NTN1 (R&D Systems) was added to the lower chamber.
Cells were allowed to migrate for 8 h and then fixed,
stained and quantitated.
For 3D Matrigel invasion assays U251MG neuro-
spheres were collected and mixed with 50 μl of Matrigel
matrix. 5 spheroids per 50 μl of Matrigel was collected.
The plug was plated on 24-well plate and allowed to
polymerize at +37 °C 30 min. DMEM/F12 culture
medium as such or supplemented with 50 ng/ml recom-
binant NTN1 was added to the wells. The growth of the
spheroids were monitored with Cell-IQ imaging system
(Chip Man Tehcnologies) and 10x objective. Each spher-
oid was imaged every 30 min for 24 h. Using Cell-IQ
software the growth of the spheroids was analyzed by
measuring its area at each imaging timepoint. In
addition the images of each spheroids were combined to
a movie using 7 frames per second display rate.
Establishment of primary GBM stem-like cell cultures
The fresh GBM tissue obtained from surgical tumor resec-
tion was processed according to previously published
protocol [16]. Shortly, the tissue pieces were minced care-
fully and washed with DMEM/F12 medium supplemented
with 100 IU/ml penicillin and 50 mg/ml streptomycin.
After washing the medium was replaced with 5 ml Tryp-
sin EDTA (Gibco) and incubated at +37 °C for 30 min.
The detachment of cells was ensured by vigorous pipet-
ting up and down every 10 min. The trypsin was inhibited
by adding 10 ml of Defined trypsin inhibitor (Gibco). The
non-dissociated tissue pieces were allowed to sediment
and the medium containing single cells was moved into a
new tube. The cells were collected by centrifuging
1000 rpm 5 min. Cells were resuspended into DMEM/F12
supplemented with 100 IU/ml penicillin, 50 mg/ml
streptomycin, EGF 20 ng/ml (R&D systems), FGF 20 ng/
ml (R&D systems) and vitamin A depleted B27 supple-
ment (Gibco) in a density of 50 000 cells/ml and plated
into cell culture flasks. The flask were incubated in cell
culture incubator for 7 days for neurospheres to form.
The culture medium was changed every second day. The
neurospheres were trypsinized and plated into new cell
culture flasks every second week.
3D stem-like cell invasion assay
U251MG cells expressing GFP and either NTN1FH or
NTN1(II)FH and primary human GBM cells, GBM9 or
GBM10, were trypsinized and counted. 1000 U251MG
cells and 1000 primary GBM cells were mixed in 100 μl
of DMEM/F12 (Gibco) and plated into U-bottom plates
(Thermo Scientific) coated with 0,5% agarose. Cells were
allowed to form spheroids by incubating them in a cell
culture incubator for 24 h. On the following day, six
spheroids were collected into Eppendorf tubes and cen-
trifuged gently, 1 min 1000 rpm. The medium was re-
moved and spheroids resuspended into 50 μl of ice-cold
Matrigel. The Matrigel and cell mixture was plated into
the well of a 24 well plate. The Matrigel droplets were
allowed to polymerize at +37 °C 30 min. Next, 1 ml of
DMEM/F12 cell culture medium was added to each well.
The growth of the spheroids were monitored with Cell-
IQ imaging system (Chip Man Tehcnologies) using 10×
objective. Both transmitted light and GFP images were
acquired. Each spheroid was imaged every 30 min for
24 h. Using Cell-IQ software the growth of the spheroids
was analyzed by measuring its area at each imaging
timepoint. In addition the images of each spheroids were
combined into a movie using 7 frames per second dis-
play rate.
Wholemount immunofluorescence staining of Matrigel
drops
The Matrigel droplets were fixed with 4% paraformalde-
hyde at room temperature for 30 min. Fixed droplets
were washed with PBS. The unspecific binding of anti-
bodies was prevented by incubating the droplets with 3%
BSA, 0,3% Tween 20 in PBS (blocking buffer) at room
temperature for 60 min. Primary antibodies were diluted
to blocking buffer, added to droplets and incubated at
+4 °C 24 h. Droplets were washed with 0,1% Tween 20
in PBS. Secondary antibodies and Hoechst were diluted
to blocking buffer and incubated with the droplets at
room temperature for 60 min. The droplets were again
washed with 0,1% Tween 20 in PBS. Finally excess salts
were removed by washing twice with milli-Q aqua. The
droplets were transferred onto microscopic slides,
mounted with Mowiol mounting medium supplemented
with 6 mg/ml DABCO anti-fading reagent and covered
with a cover glass. The spheroids were analyzed and im-
aged under Zeiss AxioImager.Z2 upright epifluorescence
microscope equipped with Hamamatsu Orca Flash 4.0
LT, 4 megapixel monochrome sCMOS camera.
The stemness of the isolated primary cells was ensured
by examining their mRNA expression of GBM stem-like
cell markers CD133, nestin, Sox2 and integrin alpha 6
with quantitative real time PCR. RNA from the cells was
collected and real-time PCR was performed as described
earlier [41]. The primers for the analysis were obtained
from Applied Biosystems. The expression levels were
normalized to the expression of GAPDH and the com-
pared to differentiated GBM10 cells that were cultured
in serum containing DMEM/F12 medium and adherent
conditions.
Statistical analysis
Error bars represent the standard deviation or standard
error of the mean of the 3–5 independent repeats of
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each experiment. Statistical significance was analyzed
with non-parametric Mann–Whitney U-test for inde-
pendent samples for continuous variables. The frequency
tables were analyzed with the χ2 test. Cumulative sur-
vival was estimated by using the Kaplan–Meyer method.
Overall survival for GBMs was calculated from the date
of diagnosis to the date of death, censoring patients who
were alive on the last follow-up date. Glioma-specific
survival was analyzed from the date of surgery of pri-
mary tumor to the date of glioma caused death, censor-
ing patients who died from other causes on the date of
death and the patients who were alive on the date of last
follow-up, and recurrence-free survival was calculated
from the date of surgery to the date of recurrence or
death if death occurred before recurrence, censoring
those patients who died of other causes and the patients
who were alive on the date of last follow-up. Multivari-
able and univariable survival analyses were done by
using Cox proportional hazards model.
Results
Netrin-1 associates with poor patient survival in low
grade gliomas
NTN1 has been observed to play a role in GBM cell
invasiveness and survival in vitro by us and others
[33, 41]. However, its association with the survival of
glioma patients has not been investigated. To address
this we used immunohistochemical stainings and ana-
lyzed NTN1 expression in tissue microarrays (TMAs)
consisting of 136 representative primary glioma sam-
ples [34, 38]. The TMAs consisted of grade II-III as-
trocytomas, oligodendrogliomas and oligoastrocytomas
and grade IV GBMs. NTN1 expression was detected
on all tumor subtypes. Within the tissue samples
40.4% of the tumors were NTN1 positive (Table 1).
NTN1 was strongly associated with astrocytic tumors
(Table 1). Within astrocytomas 77.8%, within anaplas-
tic astrocytomas 62.5% and within GBMs 77.1% of
the tumors were NTN1 positive whereas within oligo-
dendrogliomas and oligoastrocytomas only 26.7% and
36.8%, respectively, were NTN1 positive. Furthermore,
we observed that NTN1 correlated with nestin ex-
pression. Nestin has been connected to the stemness
of GBM cells and to poor prognosis of glioma pa-
tients [37, 42]. No association with gender or age at
the time of diagnosis was found (Table 1). To investi-
gate whether NTN1 expression is related to the sur-
vival of the patients we performed Kaplan-Meier
survival analysis. Both glioma-specific and recurrence-
free survival times were analyzed. Interestingly, NTN1
positivity was associated with poor glioma-specific
survival (hazard ratio [HR] = 1.73, 95% confidence
interval [95% CI] = 1.11 to 2.71; p = 0.015) (Fig. 1a)
and with shorter recurrence-free survival time (HR =
1.62, 95% CI = 1.04 to 2.53; p < 0.001) (Fig. 1b). How-
ever, when astrocytomas and oligodendroglial tumors
were analyzed separately NTN1 expression was not
significantly associated with patient survival.
Moreover, we investigated the localization of NTN1
in the tumor tissues. In all tumor types NTN1 was lo-
calized to hypoxic tumor areas and vasculature includ-
ing glomerular vessels (Fig. 1c–d). In GBM tissues
NTN1 expression was enriched to areas surrounding
the necrotic tumor core and especially to pseudopali-
sade structures (Fig. 1d). The pseudopalisading cell
areas are a typical feature of GBMs and contain actively
migrating cells [5].
Netrin-1 colocalizes with Jagged1 but not with Notch2,
Nestin or CD133 in GBM tissues
NTN1 can bind both Jagged1 and Notch2 in vitro [41].
To analyze this in human tumors we stained fresh frozen
human GBM tissue biopsies with NTN1 and Jagged1 or
Notch2 antibodies. We observed that NTN1 and
Jagged1 co-localized on the same cells (Fig. 2a) similarly
to in vitro cultured GBM cells [41]. In contrast, NTN1
and Notch2 did not co-localize in same tumor cells. In-
stead, they were expressed in neighboring cells and co-
localized within their cell-cell contacts (Fig. 2b).
Table 1 Association between netrin-1 expression and clinico-
pathological factors
Netrin-1 expression
Negative Positive P value
Histological type n = 55, % = 40.4 n = 81, % = 59.6
Astrocytoma 8 (22.2) 28 (77.8) <.0001
Anaplastic astrocytoma 6 (37.5) 10 (62.5)
Oligodendroglioma 22 (73.3) 8 (26.7)
Oligoastrocytoma 12 (63.2) 7 (36.8)
Glioblastoma 8 (22.9) 27 (77.1)
Gender
Female 27 (43.5) 35 (56.5) .499
Male 28 (37.8) 46 (62.2)
Grade
II 35 (49.3) 36 (50.7) .033
III 12 (40.0) 18 (60.0)
IV 8 (22.9) 27 (77.1)
Nestin expression
Negative 14 (51.9) 13 (48.1) .014
Positive 20 (26.0) 57 (74.0)
NA 21 11
Age at the time of diagnosis
Median/range, years 41 (23–76) 44 (17–75) .386
Abbreviations: NA data not available
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Notch signaling has been observed to promote the
stemness of the GBM cells [6, 12, 17]. Therefore, we
hypothesized that NTN1 affects the glioma stem-like
cells. To explore this further we studied NTN1 and
its co-localization with known GBM stem-like cell
markers nestin and CD133 in GBM tissues.
Interestingly, we did not observe co-localization of
NTN1 in same cells with either of these markers al-
though positive correlation of nestin and NTN1 ex-
pression was found in clinical series. Instead, NTN1
was localized to neighboring cells of nestin expressing
cells (Fig. 2c). Similar localization was observed with
anaplastic astrocytoma
A
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Fig. 1 Netrin-1 is associated with poor patient prognosis in gliomas. The association of NTN1 with the survival of glioma patients was assessed using
Kaplan-Meier survival analysis. NTN1 association to (a) glioma specific survival (hazard ratio [HR] = 1.73, 95% confidence interval [95% CI] = 1.11 to 2.71;
p = 0.015) and (b) to recurrence-free survival were analyzed (HR = 1.62, 95% CI = 1.04 to 2.53; p < 0.001). c The localization of NTN1 in low grade gliomas
was investigated by immunofluorescence staining of paraffin embedded tumor tissue. Scale bars represent 50 μm. d The localization of NTN1 in GBM
tissue was analyzed similarly as in (c). Representative images of two tumors are presented. Scale bars represent 100 μm
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CD133 (Fig. 2d). In the GBM tissues there were areas
with CD133 positive cells surrounded by NTN1 posi-
tive cells. These results suggest that NTN1 does not
localize to the stem-like cells themselves but to their
adjacent cells supporting them in the tissue.
Human surgical GBM biopsies represented primarily
the tumor core. The single invasive cells present in the
brain tissue cannot be removed in surgical operations.
However, these invasive cells are the main reason for the
relapses in patients. Therefore we wanted to investigate
the localization of NTN1 in these cells too. To mimic
the invasive front of GBM we established ex vivo human
GBM cultures. We implanted freshly collected GBM bi-
opsies in 3D Matrigel and allowed the cells to grow and
migrate for 7 days. The Matrigel plugs were then fresh
frozen and sectioned. Immunofluorescence staining of
the sections revealed that the front of the invasive struc-
tures was positive for Notch2 (Fig. 2e) and for nestin
(Fig. 2f ) suggesting stemness of the invasive cells.
Interestingly, NTN1 positive cells remained at the stalk
area of the invasive sprouts.
Netrin-1 expression enhances glioblastoma invasiveness
in vivo
To investigate how NTN1 affects GBM pathogenesis in
vivo we performed orthotopic mouse xenografts. We
first used U87MG cells because of their low endogenous
NTN1 expression. We intracranially implanted either
wild type U87MG cells (WT), NTN1 overexpressing
U87MG cells (NTN1FH) or cells expressing NTN1 cen-
tral domain (NTN1(II)FH) into mice (Additional file 1:
Figure S1A). NTN1(II)FH peptide can antagonize the ef-
fect of NTN1 in in vitro cell invasiveness [41]. The mice
were observed for 3 weeks and the tumor growth was
estimated based on the luciferase signal emitted by the
tumor cells (Fig. 3a). In the first 2 weeks of the experi-
ment there was no difference in the growth of the tu-
mors between the three groups. However, during the
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Fig. 2 Netrin-1 co-exists with glioblastoma stem like cells in tumor stroma and infiltrative sprouts. a Colocalization of NTN1 and Jagged1 was ana-
lyzed by immunofluorescence staining of human GBM tissue. Representative area of the full image is surrounded with white box and presented
as enlargement in lower panel. Scale bars represent 50 μm in full image and 20 μm in the enlargement. Merged image with all channels and sep-
arate channels of the enlargement are presented. NTN1 is marked with green, Jagged1 with red and nuclei with blue. b Colocalization of NTN1
and Notch2 was visualized by immunofluorescence staining of human GBM tissue similarly as in (a). NTN1 is marked with green, Notch2 with red
and nuclei with blue. c Colocalization of NTN1 and Nestin was analyzed by immunofluorescence staining of human GBM tissue similarly as de-
scribed in (a). NTN1 is marked with red, nestin with green and nuclei with blue. c Colocalization of NTN1 and CD133 was studied by immunofluor-
escence staining of human GBM tissue similarly as described in (a). NTN1 is marked with green, CD133 with red and nuclei with blue. e and f To
study invasive front of human GBM tumor, tissue pieces were grown in 3D Matrigel ex vivo. The location of NTN1 and nestin (e) or NTN1 and
Notch2 (f) was analyzed with immunofluorescence microscopy. The border of tumor tissue and invasive cells is implicated with dashed line. En-
largement of the boxed area is presented. In the enlargement white arrow points the direction of the migration. Green arrows point to NTN1 posi-
tive cells and red arrows Nestin positive cells in (e) and Notch2 positive cells in (f)
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third week the NTN1FH tumors started to grow very
rapidly. In addition, the NTN1FH tumors had spread all
around the head of the mice and in some mice even
along their spine (Fig. 3b–c). Interestingly, the growth of
the NTN1(II)FH expressing tumors did not significantly
differ from the WT tumors (Fig. 3b and d). The number
of photons emitted were slightly decreased and the loca-
tion of tumors restricted to the head of the mice
(Fig. 3d). This may be due to the lack of endogenous
NTN1 expression in the U87MG cell-line.
To investigate how inhibition of the function of NTN1
affects GBM growth we performed intracranial xeno-
grafts using U373MG cell line. These cells endogenously
express NTN1 [41] and grow infiltratively in vivo [2, 8].
We implanted either wild type or cells expressing either
NTN1FH or NTN1(II)FH peptide (Additional file 1: Fig-
ure S1B) into mice brains and followed the tumor
growth similarly to U87MG xenografts.
The growth of U373MG tumors was overall much
slower than U87MG cells. We followed the mice for
52 days after tumor cell injection. Similarly to U87MG
xenografts, tumors in all groups grew similarly to each
other in the beginning (Fig. 3e–f ). After 6 weeks the
groups began to display differences in their growth. Both
the control tumors and NTN1FH tumors grew all
around the mouse head area and also spread along the
spine of the mice whereas the NTN1(II)FH tumors grew
exclusively around the head area (Fig. 3g–i). Considering
Fig. 3 Netrin-1 promotes glioblastoma growth in vivo. a–d U87MG or (e–i) U373MG cells expressing firefly luciferase and full-length NTN1
(NTN1FH) or its central domain (NTN1(II)FH) were intracranial implanted into nude mice. Five mice per cell-line was xenografted. a, e and f The
growth of the tumors was followed with bioluminescent imaging. Photons emitted by the tumor were recorded and quantitated. The photons
emitted by the U373MG xenografts were quantitated separately from the head area of the mice (e) and together from the head and spine (f).
Growth curves represent the average photons/second emitted by the tumors in each group. Error bars represent the standard error of the mean.
* p value is <0,05. b-d and f-h Representative image of mice in each xenograft group at the experiment end point are presented. The color bars
indicate the intensity of photons emitted by the tumor. The color bar scales are set on equal levels within the groups of U87MG xenografts (b-d)
and within the groups of U373MG xenografts (f-h)
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the emitted photons only from the head area of the mice
we could not observe any significant differences between
the groups (Fig. 3e). However, the signal from both the
head and the spine of the mice revealed a significant de-
crease on the photons within NTN1(II)FH group
(Fig. 3f ). There was no increase on the invasiveness
within the NTN1FH group, possibly due to the en-
dogenous expression of NTN1 in U373MG cells. Taken
together these results suggest that NTN1 is an import-
ant regulator of GBM growth and invasiveness in vivo
and its inhibition prevents the diffusive growth of GBM.
After sacrificing the mice, we harvested their brains
and analyzed the growth and invasiveness of the tu-
mors by staining tissue sections. First, the expression
of NTN1FH and NTN1(II)FH both in U87MG and
U373MG xenograft tumors was confirmed (Additional
file 1: Figure S1C and D). We next analyzed whether
the differences observed in the xenograft tumor
growth were due to altered cell proliferation. The pro-
liferation rates of cultured cells used for xenografts
were measured using EdU incorporation assay. We ob-
served slight increase of U87MG cell proliferation
upon NTN1FH expression (Additional file 1: Figure
S1E). However, we did not observe similar effect in
U373MG cells (Additional file 1: Figure S1D). Consist-
ently with luminescence measurements, the control
and NTN1(II)FH U87MG cells had formed a solid
tumor with few invasive structures. Furthermore,
NTN1 expression increased tumor growth and altered
the growth into more invasive phenotype (Fig. 4a–c).
The cells were spreading along the blood vessels adja-
cent to the tumors (Fig. 4b). To quantify the invasive-
ness of the tumor cells we stained the tissue sections
with human specific lamin A/C antibody which en-
abled us to distinguish the human cells from the
mouse tissue. The invasive cells were then counted in
a double blinded manner. Significant increase in the
number of invasive colonies was observed in the
NTN1FH U87MG tumors (Fig. 4d) and consistently
lower number in the NTN1(II)FH U373MG tumors
(Additional file 2: Figure S2).
Because NTN1 expression correlated with nestin posi-
tivity in human glioma TMA we analyzed nestin expres-
sion in the GBM xenografts. Unexpectedly, we detected
that the invasive edge of the U87MG NTN1FH tumors
was strongly nestin positive in NTN1FH tumors but not
in control or NTN1(II)FH tumors (Fig. 4e–g). Further-
more, the border of tumor stroma and the normal
mouse brain tissue was clear-cut in the control and
NTN1(II)FH tumors but more diffuse in NTN1FH tu-
mors. We further stained the NTN1FH tumor sections
for nestin and HA to localize NTN1 positive cells in the
tumors. We observed that the invasive structures con-
sistently showed an assembly where the nestin positive
cells were on the leading edge whereas NTN1 positive
cells were following them (Fig. 4h). We also observed
similar pattern with Notch2 staining (Fig. 4i). These
findings are consistent with the observations in the hu-
man ex vivo GBM models where the leading cells of the
invasive structures were nestin and Notch positive
whereas NTN1 positive cells were in the stalk area of
the structures (Fig. 2e–f ).
Netrin-1 increases the percentage of GBM stem-like cells
and enhances their motility
To explore how NTN1 affects the GBM stem-like cells,
we cultured both wild type and NTN1 overexpressing
U251MG GBM cells under conditions that favor neural
stem cell proliferation. Under these culture conditions
stem-like cell proliferation leads to the formation of a
spheroid called neurosphere [40]. The number of neuro-
spheres formed was calculated and used as an estimate
of the number of stem-like cells within the initial popu-
lation (Fig. 5a). Interestingly, NTN1 overexpression led
to 16-fold higher neurosphere formation compared to
wild-type cells. These neurospheres also expressed more
stemness markers Sox2, nestin and integrin alpha6 com-
pared to normal U251MG cells (Fig. 5b–c). This
suggests that the initial NTN1 overexpressing cell popu-
lation contained a higher number of stem-like cells and
that NTN1 plays a role in their maintenance.
Next, we investigated how NTN1 affects the motility
of the stem-like cells. We dissociated the U251MG neu-
rospheres and plated the cells on top of Matrigel coated
Boyden chamber. After 8 h the cells that had migrated
through the chamber were quantified. Addition of
50 ng/ml of recombinant NTN1 (rNTN1) as attractant
to the lower chamber significantly increased the number
of invading cells (Fig. 5d). To better mimic the 3D tissue
environment, we implanted the U251MG neurospheres
in 3D Matrigel and monitored their growth for 24 h.
Similarly to the Boyden chamber assay, addition of
rNTN1 to the medium enhanced the motility of the
cells: the spheroids spread much faster upon rNTN1
addition (Fig. 5e). Furthermore, the control spheroids
remained more compact compared to rNTN1 treated
(Fig. 5f, Additional file 4 and Additional file 5). These re-
sults further confirm that rNTN1 regulates the motility
of GBM stem-like cells.
Freshly isolated GBM cell-lines that are kept under the
stem-like cell proliferation favoring culture conditions are
a better model for investigating glioma stem-like cells than
long cultured cell lines [1, 40]. Therefore we established
primary GBM stem-like cell cultures (GBM9 and GBM10)
from surgical GBM biopsies. The expression of GBM
stem-like cell markers CD133, nestin and Sox2 in stem-
like cell cultures was higher compared to counterpart cells
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cultured in serum containing medium, confirming their
stemness (Additional file 3: Figure S3A).
GBM tumors are heterogeneous and contain both
stem-like cells and differentiated tumor cells. To mimic
this we dispersed stem-like GBM9 or GBM10 spheroids
and mixed these cells with GFP labelled U251MG cells
cultured in serum containing medium. Furthermore, we
had observed that NTN1 induces invasion mode where
nestin positive cells were enriched at the invasive front
of the tumors and NTN1 positive cells were following
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Fig. 4 Netrin-1 increases the invasiveness of GBM stem-like cells in vivo. a–c The tumor growth in xenograft models was evaluated by immunohisto-
chemistry with human specific nestin antibody. Representative tile images of tissue sections of each U87MG xenograft group are presented. The area
covered with tumor is surrounded with dashed line. d To evaluate the effect of NTN1FH or NTN1(II)FH on GBM cell invasiveness xenograft tissue section
were stained with human specific Lamin A/C antibody and the invasive colonies were counted. The average number of invasive colonies in each
group is presented. Error bars represent +/− standard error of the mean. * p value is <0,05. e–g Immunofluorescence microscopy images of the tumor
border show the infiltrative growth of nestin positive GBM cells in each U87MG xenograft groups. Scale bars represent 100 μm. h–i The invasive tumor
sprouts of U87MG-NTN1FH tumors were further characterized with immunofluorescence stainings of the tissue sections. Dashed line borders the tumor
stroma and the white arrow points the direction of invasion. In (h) red arrows point NTN1 positive cells and green arrows Nestin positive cells. In (i) green
arrows point NTN1 positive cells and red arrows the Notch2 positive cells. Scale bars represent 50 μm
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them (Figs. 2e–f and 4e–i). To explore this we expressed
NTN1FH or NTN1(II)FH peptides in the U251MG cells
and mixed them with GBM9 or GBM10 cells. The mixed
cell populations were allowed to form spheroids under
serum free conditions and embedded into 3D Matrigel
matrix and observed for 24 h.
The spheroids composed of GBM9 and control or
NTN1FH expressing U251MG invaded diffusively into the
Matrigel (Fig. 6a, Additional file 6 and Additional file 7).
There were two types of sprouts invading: sprouts where
the GFP positive U251MG cells were leading and sprouts
where GBM9 cells were leading. In contrast, the spheroids
composed of GBM9 and U251-NTN1(II)FH cells invaded
in more compact manner and presented only GFP positive
sprouts (Fig. 6a, Additional file 8). To quantify the ratio of
sprouts we fixed the invaded spheroids and counted the
percentage of GBM stem-like cell or U251MG guided
sprouts in the different spheroid types (Fig. 6b). In GBM9/
10-U251 and in GBM9/10-U251-NTN1FH spheroids both
sprout types existed at about equal proportions. In GBM9/
U251MG-NTN1(II)FH spheroids more than 80% of the
sprouts were led by U251GM cells (Fig. 6b).
We also analyzed the differences in the overall inva-
siveness of the different mixed spheroids by measuring
the area of the spheroid in various time points. We ob-
served that NTN1FH expression slightly increased the
spheroid area while the NTN1(II)FH decreased it (Add-
itional file 3: Figure S3B). These observations are in line
with the differences in the xenograft growth.
As a portion of cultured U251MG cells have stem-like
properties and nestin expression, the co-culture spher-
oids were also stained for nestin. In the GBM9/U251-
Fig. 5 Netrin-1 promotes the maintenance and motility of U251MG stem-like cells. a Either wild-type or NTN1 overexpressing U251MG cells were
cultured under condition that favor neural stem cell proliferation for 3 weeks. The formed neurospheres were calculated. The number of the neu-
rospheres is presented as relative to the wildtype U251MG. Error bars represent SD. * = p < 0,05. b The formed U251MG neurospheres were col-
lected and the expression of stem cell markers was evaluated with quantitative real time PCR. The mRNA expression is normalized to the
expression of GAPDH. The results are expressed as relative to the mRNA expression levels of U251MG cells cultured under standard conditions.
Error bars represent the standard deviation. c The expression of the markers was also confirmed with immunofluorescence microscopy. Scale bars
represent 50 μm. d U251MG neurospheres were dissociated and plated into Matrigel coated Boyden chambers. Cells were allowed to invade for
8 h and then quantitated. Number of invaded cells are presented as relative to the control group. Error bars represent SEM and * = p < 0,05. e
Neurospheres were embedded into 3D Matrigel matrix and monitored for 24 h. The area of the spheroids was measured at the starting and end-
ing point of the experiment. The graphs represent the relative change in the area of the spheroid. Error bars represent SEM and * = p < 0,05. f Im-
ages represent the endpoint of the 3D Matrigel invasion assays. The invasion of the control spheroids is presented also on Additional file 4: Video
1 and the invasion of the rNTN1 treated spheroids in Additional file 5: Video2. Scale bars represent 200 μm
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Fig. 6 Netrin-1 promotes the motility of the primary glioblastoma stem-like cells. a Primary human GBM stem-like cells, GBM9, were mixed with
GFP positive U251MG cells, that were either wildtype (U251), full length NTN1 producing (U251-NTN1FH) or NTN1 central domain producing
(NTN1(II)FH). The spheroids were implanted into 3D Matrigel and their growth was monitored with Cell-IQ imaging system for 24 h. Gray arrows
mark sprouts that are led by GBM9 cells. Green arrows mark sprouts that are led by GFP-positive U251MG cells. The invasion of the spheroids is
presented also on Additional file 6: Video3, Additional file 7: Video4 and Additional file 8: Video5. b The number of sprouts led by the GFP-
negative (GFP-) primary cells or GFP-positive (GFP+) U251MG cells were quantitated. The distribution as percentage is presented. Error bars repre-
sent SD. * = p < 0,05. c After 24 h 3D Matrigel invasion spheroids consisting of GBM9 cells mixed with U251-NTN1FH or U251-NTN1(II)FH were
fixed and used for immunofluorescence staining against Nestin and HA. HA marks either full-length NTN1 (NTN1FH) or the central fragment of
NTN1 (NTN1(II)FH)
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Fig. 7 (See legend on next page.)
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NTN1FH spheroids practically all of the sprouts were
nestin positive whereas the HA positive NTN1 express-
ing cells were mostly either in the core of the spheroids
or in the stalk area of the sprouts (Fig. 6c). In contrast,
in the GBM9/U251-NTN1(II)FH spheroids the majority
of the sprouts were HA positive indicating that they are
of U251MG origin. Even in these spheroids the tips of
the invading cells were nestin positive. Furthermore, we
investigated whether the sprouts exhibited differences in
Notch activation. Interestingly, we observed that in
NTN1FH spheroids the sprouts led by GFP and HA
negative cells were positive for Notch cleavage which in-
dicates the signaling activation (Fig. 7a and b). Similarly
in spheroids containing control U251 cells Notch posi-
tive GFP negative sprouts were observed. In contrast, in
the presence of U251-NTN1(II)FH the staining for ac-
tive Notch was less intense. In these spheroids all of the
invasive sprouts were GFP and HA positive, indicating
that the invasive cells were of U251 origin and expressed
NTN1(II)FH (Fig. 7a and b). Taken together these re-
sults suggest that NTN1 regulates the GBM invasiveness
by promoting the motility of the GBM stem-like cells
and the inhibition of the NTN1 signaling with
NTN1(II)FH peptide reduces the invasiveness of espe-
cially GBM stem-like cells.
Discussion
GBM is the most severe human brain cancer. Despite
numerous efforts within recent years, no curative
treatments have been discovered. In addition to the
difficult location, GBM tumors are very heterogeneous
and spread aggressively. Their infiltrative growth type
hinders the surgical removal of all tumor cells. Be-
cause GBM cells are enormously plastic and can re-
semble characteristics of stem cells the remaining
cells rapidly grow into secondary tumors [3, 4]. In the
current research we provide a novel insight into the
regulation of invasiveness of GBM using in vivo and
in vitro models.
NTN1 is a secreted extracellular matrix component.
In tissue microarray analysis of gliomas NTN1 was
strongly linked to poor patient prognosis and especially
to tumors of astrocytic origin. This subtype of gliomas
are known to be more invasive than the oligodendrocy-
tic tumors [26]. Furthermore, NTN1 located on hyp-
oxic tumor areas that contain motile GBM stem-like
cells. In orthotopic xenograft models, the expression of
NTN1 increased the total tumor mass. Netrin-1 over-
expression caused a subtle increase in tumor cell prolif-
eration, which may explain this increase to some
extent. However, netrin-1 was able to alter the behavior
of non-invasive U87MG GBM cell-line into more diffu-
sively invading. Similarly, the inhibition of NTN1 sig-
naling by a recombinant NTN1(II)FH peptide could
reverse the phenotype of diffusively invasive U373MG
cells into less invasive. Taken together, these results
describe NTN1 as a powerful regulator of glioma
invasiveness.
During developmental processes NTN1 is linked to
the regulation of cell motility and stem cell self-
renewal. It increases the motility of blood derived mes-
enchymal stem cells via matrix metalloprotease
dependent breakdown of E-cadherin [19]. In addition,
NTN1 increases the self-renewal of embryonic stem
cells by preventing classical NTN1 receptor, UNC5B,
dependent apoptosis [25]. During the lung bud devel-
opment, NTN1 is accumulated to the stalk area of the
developing lung bud but not the growing tip of the
branch [21]. Similarly, in the developing mammary
gland, NTN1 is expressed by the pre-luminal cells that
are located behind the migrating cap cells [7]. Here, we
observed similar NTN1 mediated regulation of cancer
stem-like cell motility and self-renewal. We observed
that in the NTN1 expressing U87MG xenografts tu-
mors the boundary of the tumor and the normal brain
tissue was positive for stemness indicating marker nes-
tin. In the control tumors or those expressing
NTN1(II)FH peptide this was not observed. Interest-
ingly, when we examined the invasive colonies or
sprouts that were growing away from the tumor core,
we observed a distinct assembly. The cells in the lead-
ing edge were positive for nestin whereas the cells in
the stalk area of the sprouts were NTN1 positive. Simi-
lar structures were visible in both xenograft models and
in ex vivo human GBM tissue cultures. The structure
of these sprouts was similar to those observed in NTN1
guided lung and mammary gland morphogenesis [7,
21]. These findings support the role of NTN1 as regula-
tor of stem cell motility.
In our previous work we found that NTN1 can upregu-
late Notch2 signaling in human GBM cells in vitro [41]. In
addition, elevated Notch signaling has been connected to
the maintenance of the stem-like cells in GBM tumors [6,
12, 17] and to the upregulation of nestin expression [32].
(See figure on previous page.)
Fig. 7 Invasive primary GBM cells increase Notch2 activation upon NTN1FH expression. a After 24 h 3D Matrigel invasion spheroids consisting of
GBM10 cells mixed with control U251, U251-NTN1FH or U251-NTN1(II)FH were fixed and used for immunofluorescence staining against cleaved
Notch2 and HA. HA marks either full-length NTN1 (NTN1FH) or the central fragment of NTN1 (NTN1(II)FH). b Similarly as in (a) the invaded spheroids
consisting of GM10 cells mixed with GFP positive U251MG cells were stained against cleaved Notch2. c Model of NTN1 induced invasion of GBM cells
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Therefore we speculated that the NTN1 induced upregu-
lation of invasiveness and stem-like phenotype of GBM
cells is mediated by Notch signaling. Indeed, we observed
that when NTN1 was overexpressed in GBM cells in vitro
their percentage of stem-like cells was increased. This sug-
gests that NTN1 promotes the maintenance of the stem-
like cells within the population. In the human GBM tissue
NTN1 colocalized with a known Notch ligand Jagged1.
On the contrary, Notch2 and NTN1 were not expressed
in same cells but they did colocalize on the cell-cell con-
tacts of neighboring cells. Similar coexpression in neigh-
boring cells was observed with NTN1 and GBM stemness
markers CD133 and nestin. Furthermore, the nestin posi-
tive leading edges of the invasive colonies in both the
xenograft tumors and in the ex vivo cultured GBM tumors
were also positive for Notch2. Moreover, NTN1 inhibition
in the co-culture of human primary GBM cells and
U251MG cells significantly decreased the ratio of invasive,
Notch activated primary stem-like cells. Taken together,
these findings provide a new mechanism for GBM inva-
siveness. NTN1 in the stalk area of the invasive structures
can activate the Notch signaling in the adjacent cells that
form the leading edge of the sprouts (Fig. 7c). This allows
the maintenance of stem like characteristics of the leading
cells which is a great advantage because the stem like cells
are very plastic and motile.
Infiltrative invasiveness and the stemness of the
tumor cells are hallmarks of GBM and also the main
reasons for the treatment failure [23]. The current
treatment regimens offer only modest prolongation of
the survival but do not cure the disease [39]. There-
fore there is a need for new treatment options. Here
we describe NTN1 as a novel regulator of GBM inva-
siveness and stemness. By inhibiting NTN1 signaling
both of these phenotypes can be targeted. Therefore,
NTN1 signaling inhibition could offer a powerful way
to target GBM. Furthermore, we have previously engi-
neered a NTN1(II)FH peptide that can overcome the
effects of the full-length NTN1 [41]. Here we provide
evidence that this peptide can inhibit GBM growth in
vivo by specifically targeting the stem-like cells. This
peptide may be of therapeutic value for GBM
treatment.
Conclusions
This study demonstrates that NTN1 is an important
regulator of stemness and motility of glioblastoma cells.
Although previous studies have implicated that NTN1
may regulate cancer cell invasion this is the first time a
connection to cancer stem cells is described. Further-
more, it deciphers a novel mechanism where NTN1 acti-
vates Notch signaling and subsequent stemness in
invasive glioblastoma cells.
Additional files
Additional file 1: Figure S1. NTN1FH and NTN1(II)FH are expressed in
U87MG and U373MG xenografts. (A) U87MG cells stably expressing
NTN1FH and NTN1(II)FH were lysed and immunoblotted against HA.
Positions of known protein markers are presented. (B) Expression of
NTN1FH and NTN1(II)FH in U373MG cells was similarly validated as in (A).
(C) and (D)NTN1FH and NTN1(II)FH expression was confirmed in U87MG
xenograft tumors (C) and U373MG xenograft tumors (D) with
immunofluorescence staining against HA-tag. (E) and (F) The effect of
NTN1FH and NTN1(II)FH to cell proliferation was analysed using EdU in-
corporation assay and automated image analysis. Effect to U87MG cells
(E) and to U373MG cells was analyzed. (PDF 1832 kb)
Additional file 2: Figure S2. NTN1(II)FH alters U3737MG invasiveness
in vivo. The number of invasive colonies in U373MG xenografts was
analyzed similarly as in Fig. 4D. (PDF 1351 kb)
Additional file 3: Figure S3. Primary human GBM cells express stem
cell markers. (A) The stemness of primary GBM cells was assessed by
quantitative real-time PCR. The expression was normalized to GAPDH ex-
pression. Error bars represent the standard error of the mean. (B) Primary
stem-like GBM cells were mixed with U251 cells and embedded into
Matrigel. The spheroids were allowed to invade for 24 h. The spheroids
were imaged every 15 min. The area covered by the spheroids were
measured in multiple time points. The growth curves represent the
change of the area of spheroids. Error bars represent SEM. (PDF 1365 kb)
Additional file 4: Invasion of U251MG neurospheres in 3D Matrigel.
Video (file format QuickTime, extension.mov) represents the invasion of
U251MG neurospheres that are embedded into 3D Matrigel. Images were
captured with Cell IQ imaging system using 10x objective. Frames were
collected every 30 min during 24 h. Display rate is 7 frames/second.
Video is related to Fig. 5f.
Additional file 5: Invasion of rNTN1 treated U251MG neurospheres in
3D Matrigel. Video (file format QuickTime, extension.mov) represents the
invasion of U251MG neurospheres that are embedded into 3D Matrigel
and treated with recombinant NTN1. Images and video were captured
similarly as in Additional file 4. Video is related to Fig. 5f.
Additional file 6: Invasion of GBM9/U251MG mixture spheroids in 3D
Matrigel. Video (file format QuickTime, extension.mov) represents the
invasion of spheroids consisting of GBM9 and U251MG-plvx cells. The
spheroids were embedded into 3D Matrigel and monitored for 24 h.
Transmitted light and epifluorescence images were captured with Cell IQ
imaging system using 10x objective. Frames were collected every 30 min.
Display rate is 7 frames/second. Frames of various time points are pre-
sented in Fig. 6b.
Additional file 7: Invasion of GBM9/U251MG-NTN1FH mixture spheroids
in 3D Matrigel. Video (file format QuickTime, extension.mov) represents
the invasion of spheroids consisting of GBM9 and U251MG-NTN1FH cells.
The spheroids were embedded into 3D Matrigel and monitored for 24 h.
Images and video were captured similarly as in Additional file 6. Frames
of various time points are presented in Fig. 6b.
Additional file 8: Invasion of GBM9/U251MG-NTN1(II)FH mixture
spheroids in 3D Matrigel. Video (file format QuickTime, extension.mov)
represents the invasion of spheroids consisting of GBM9 and U251MG-
NTN1(II)FH cells. The spheroids were embedded into 3D Matrigel and
monitored for 24 h. Images and video were captured similarly as in Add-
itional file 6. Frames of various time points are presented in Fig. 6b.
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